TAPAZOLE (methimazole) by Pfizer is thyroid hormone synthesis inhibitors [moa]. First approved in 1950.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
TAPAZOLE (methimazole) is an oral small-molecule thyroid hormone synthesis inhibitor used to treat hyperthyroidism by blocking thyroid peroxidase and reducing thyroid hormone production. It is a first-line antithyroid agent indicated for patients with Graves' disease, toxic nodular goiter, and thyroid storm preparation. The drug works by inhibiting the incorporation of iodine into thyroid hormones, effectively lowering circulating T3 and T4 levels.
A long-established product approaching loss of exclusivity with moderate competitive pressure (30/100) presents limited growth but stable maintenance opportunities.
Thyroid Hormone Synthesis Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TAPAZOLE offers stable, lower-risk career roles in maintenance and defensive positioning rather than growth or innovation. With minimal linked job postings and an approaching LOE, career advancement may be limited unless you seek transition to higher-growth franchises within Pfizer.
Worked on TAPAZOLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.